国家医保局发布医疗服务价格立项指南 优质手术机器人“工资”更高

Core Insights - The market share of domestic surgical robots in China has increased from 32.61% in 2023 to 48.89% in 2024, indicating significant growth in the sector [1] - Despite advancements, the utilization rate of robots in surgeries in China is only 6.33%, compared to 42% in the United States, highlighting room for improvement in the clinical application of surgical robots [1] Group 1: Changes in Pricing Logic - The previous pricing model for surgical robots was based on factors like surgical approach and brand, leading to unclear charges and increased patient burden [2] - The new guidelines introduce three pricing categories: navigation, participation in execution, and precise execution, allowing for a more transparent and fair pricing structure [2] - This "pay for performance" approach rewards robots that demonstrate higher participation and clinical value, potentially excluding less effective products from benefiting financially [2] Group 2: Clinical Value and Market Recognition - The guidelines acknowledge the clinical value of surgical robots, which may shorten the adoption cycle for new technologies and enhance market recognition for self-developed products [3] - Companies like Shenzhen Precision Medical Technology have successfully completed over 14,000 clinical surgeries with their robotic systems, reinforcing the importance of clinical validation [3] Group 3: Expansion of Precision Surgery - The guidelines aim to broaden the application of precision surgeries by enabling remote surgical assistance, which can be particularly beneficial for patients in remote areas [4] - The introduction of a "remote surgical assistance fee" will facilitate the use of surgical robots in telemedicine, allowing experts in resource-rich areas to assist patients elsewhere [4] - The national health authority plans to unify medical service pricing across the country, ensuring access to high-quality and affordable medical services for the public [4]